Identification of type II inhibitors targeting BRAF using privileged pharmacophores

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• The V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) protein kinase is frequently mutated in human cancers.
• The BRAF V600E mutation leads to constitutive activation of the RAS/RAF/MEK/ERK signaling pathway, driving cancer progression.
• BRAF is a validated therapeutic target, necessitating the development of novel inhibitors.

Purpose of the Study:

• To design and synthesize novel hybrid pharmacophores by combining phenylaminopyrimidine and unsymmetrical diaryl urea motifs.
• To identify selective inhibitors targeting BRAF and the oncogenic BRAF V600E mutation.
• To evaluate the in vivo antitumor efficacy of lead compounds in a relevant cancer model.

Main Methods:

• Hybrid pharmacophore design integrating phenylaminopyrimidine and diaryl urea structures.
• Synthesis and in vitro evaluation of a new series of chemical compounds.
• In vivo efficacy study of the lead compound in an A549 human non-small-cell lung cancer xenograft model.
• Molecular docking to elucidate the binding mechanism of the lead compound.

Main Results:

• Successful identification of selective inhibitors for BRAF and BRAF V600E.
• Lead compound 3 demonstrated sustained antitumor efficacy upon daily oral administration in a lung cancer xenograft model.
• Molecular docking studies indicated that compound 3 likely functions as a type II kinase inhibitor, binding to the DFG-out conformation of BRAF.

Conclusions:

• The novel 4-phenylaminopyrimidine urea scaffold is effective in developing selective BRAF inhibitors.
• Lead compound 3 exhibits promising therapeutic potential for BRAF V600E-mutated cancers, particularly non-small-cell lung cancer.
• The findings support BRAF as a target and highlight the potential of type II kinase inhibitors in cancer therapy.